$NNVC

NANOVIRICIDES, INC.

NanoViricides develops nanoviricides, a class of antiviral drugs based on nanomedicine technology. Its drug candidates are designed as host-mimetic or direct-acting nanomachines that bind to and destroy virus particles. The company is clinical stage and has no customers, products or revenues to date. Its most advanced candidate, NV-387, is being developed in oral syrup and oral gummy formulations for viral infections. Other programs include HerpeCide for herpesviruses, HIVCide for HIV, and preclinical candidates for viruses including Dengue and Ebola. NanoViricides manufactures drug substances and formulations at its facilities in Shelton, Connecticut, which also support drug development, analytical testing, packaging and labeling. It licenses intellectual property from TheraCour Pharma and has out-licensed NV-CoV-2 and NV-CoV-2-R for development and commercialization in India, with royalties tied to commercialization by collaborator KMPL. The company is headquartered in Shelton, Connecticut.

1
0
1

No SEC Form 4 filings for $NNVC in the last 30 days.

See all $NNVC insider activity →
Med

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

NanoViricides reports Q3 results

NanoViricides reported Q3 2026 results, stating cash and cash equivalents of $2.98 million as of September 30, 2026, according to the company.

NanoViricides: An Investigational Drug to Tackle Measles Outbreaks

NanoViricides (NNVC) is advancing its investigational drug NV-387 for measles treatment, citing recent outbreaks and deaths. The drug has shown promise in animal models and is in Phase II trials for Ebola and Mpox. NV-387 has received FDA designations, including Rare Pediatric Disease Drug, which could lead to a Priority Review Voucher.

NNVC sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 2 news stories mentioning NNVC (NANOVIRICIDES, INC.). Coverage has been balanced: 1 bullish, 0 neutral, and 1 bearish.

Recent NNVC coverage spans financial news, technology and earnings.

What's driving NNVC

AlphAI scores every news story that mentions NNVC with an AI model for sentiment and relevance, and aggregates insider trades from NANOVIRICIDES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $NNVC

Score

NanoViricides, Inc. Has Filed its Quarterly Report - Broad-Spectrum Antiviral Drug NV-387 Oral Gummies Has Entered Two Separate Phase II Clinical Trials - One to Treat Ebola Bundibugyo Virus Disease, and Another to Treat Mpox

NanoViricides, Inc. (NYSE American:NNVC) filed its Q3 2026 report, revealing Phase II trials for NV-387 Oral Gummies to treat Ebola and Mpox. The company has $2.98M in cash and $9.56M in total assets, but warns of insufficient funding for operations beyond November 2027.

NanoViricides, Inc. (NNVC) NV-387 Ebola Trial Seen Advancing to Phase IIB

NanoViricides, Inc. (NNVC) reported progress in its Phase IIA trial for NV-387 Oral Gummies Ebola in the DRC, targeting 20 patients with a 28-day survival endpoint. The trial is expected to advance to Phase IIB upon completion. The company aims to progress NV-387 across multiple indications, with a clearer catalyst expected upon IIA completion and IIB start.

$NNVCMedAI 8/10

A drug being tested for Ebola showed no harmful effects in a young-mouse safety study

NanoViricides, Inc. (NNVC) announced that its antiviral drug NV-387 showed strong safety and tolerability in a juvenile mouse study, paving the way for pediatric clinical trials. NV-387 is in Phase II trials for Ebola and Mpox, with potential pediatric cohorts if successful. The company also has plans for a Phase II trial for Measles, which has received Orphan Drug and Rare Pediatric Disease Designations from the FDA.

$NNVCMedAI 8/10

The current Ebola outbreak killed 4,339 people by Oct. 10. An oral drug trial is enrolling.

NanoViricides (NNVC) reports progress in its Phase IIA clinical trial of NV-387 oral gummies for Ebola treatment. The trial aims to evaluate safety and tolerability in patients with varying severity levels of the Bundibugyo Ebola virus in the DRC. As of October 10, 2026, the outbreak has resulted in 4,339 deaths out of 9,000 confirmed cases, according to the WHO. The company expects to announce results on safety and potential efficacy soon.

NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'

Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.

$NNVCLowExec change

NANOVIRICIDES, INC. (NNVC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

NANOVIRICIDES, INC. (NNVC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Compensatory Arrangements of Certain Officers. Extension Employment Agreement - Anil Diwan On September 25, 2026, NanoViricides, Inc. (the “Registrant”) entered into an Extension Agreement effective July 1, 2026 (the “Diwan Extension”) of the Employment Agreement with

Related tickers